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Abstract
Background: Several groups have employed genomic data from subchronic chemical toxicity studies in rodents (90 days) to
derive gene-centric predictors of chronic toxicity and carcinogenicity. Genes are annotated to belong to biological
processes or molecular pathways that are mechanistically well understood and are described in public databases.
Objectives: To develop a molecular pathway-based prediction model of long term hepatocarcinogenicity using 90-day
gene expression data and to evaluate the performance of this model with respect to both intra-species, dose-dependent
and cross-species predictions.
Methods: Genome-wide hepatic mRNA expression was retrospectively measured in B6C3F1 mice following subchronic
exposure to twenty-six (26) chemicals (10 were positive, 2 equivocal and 14 negative for liver tumors) previously studied by
the US National Toxicology Program. Using these data, a pathway-based predictor model for long-term liver cancer risk was
derived using random forests. The prediction model was independently validated on test sets associated with liver cancer
risk obtained from mice, rats and humans.
Results: Using 5-fold cross validation, the developed prediction model had reasonable predictive performance with the area
under receiver-operator curve (AUC) equal to 0.66. The developed prediction model was then used to extrapolate the
results to data associated with rat and human liver cancer. The extrapolated model worked well for both extrapolated
species (AUC value of 0.74 for rats and 0.91 for humans). The prediction models implied a balanced interplay between all
pathway responses leading to carcinogenicity predictions.
Conclusions: Pathway-based prediction models estimated from sub-chronic data hold promise for predicting long-term
carcinogenicity and also for its ability to extrapolate results across multiple species.
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Introduction
There is push to use a broad array of biological data in toxicity
testing to improve reliability and provide reasonably quick
indications of animal and human toxicity of chemical compounds.
The National Toxicology Program (NTP) ’s High Throughput
Screening (HTS) [1] and the Environmental Protection Agency’s
ToxCast programs [2] are efforts in this direction. These efforts
have been initiated in light of the fact that for a lot of the 100,000
chemicals in commerce in the U.S. and Europe, information on
toxicity is extremely limited [3]. Data provided from the long term
chronic testing of chemicals on animals, like those from NTP’s
two-year cancer bioassay though invaluable in providing carcino-
genicity information in vivo over a wide range of animal tissues and
across multiple doses, is not suitable when one needs to rapidly
identify potential harm from chemical exposure. Over the past
approximately 40 years, only around 600 chemicals have been
tested by the NTPs in their two-year cancer bioassay and only
about 5–6 times this number have been tested worldwide.
The goal of toxicity testing is ultimately to protect human
health. Even though the two-year cancer bioassay is performed on
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rats and mice, there is considerable data supporting its use to
screen for carcinogens in humans [4]. The HTS and ToxCast
programs are performed on cell lines; these can be both human
and animal and thus provide a logical path for extrapolation
between species. However, cell lines are distantly removed from a
functional whole organism so it becomes necessary to extrapolate
the in vitro results from the various cell lines to the human in vivo
context.
An alternative to the cell-based assays in the HTS and ToxCast
programs is the use of short term molecular data (typically gene
expression) from exposed animals or humans to predict future
toxicity or carcinogenicity. Others have used gene expression data
based classifiers that would distinguish a toxin or carcinogen from
a non-toxin or non-carcinogen [5,6,7,8,9,10,11,12,13,14]. These
representative examples demonstrate different approaches to
predictive toxicology using gene expression data obtained from
rodents dosed over a period of time ranging from a day to 90 days.
In all of the published studies, chemicals were classified in a binary
fashion (for example, attempts were made to classify chemicals as
being carcinogenic or not). Such an approach underutilizes the
results from the chronic studies in light of the fact that a
continuous statistic was used to evaluate the data originally (e.g. p-
value from the Fisher exact test or the trend statistic from the Poly-
3 test [15]) and a considerable amount of other biological
information was brought to bear on a final evaluation. This leads
to obvious loss of information regarding the differential toxicity of
different compounds at their relevant doses.
A characteristic of gene expression data is the very large features
(genes) to samples (animals) ratio. This characteristic contributes to
the lack of identification of robust classifiers as demonstrated by
[16] – multiple classifiers give the same prediction accuracies
which quite often are 100 percent. This could mean that the data
was over-fit or there are correlations between genes that allow for
alternate sets of genes to server as predictors. In the second
scenario of correlated gene expressions, this would suggest the use
more of mechanistically-relevant prediction models where the data
is examined at the biological pathway level rather than at the gene
level.
In order to gauge quantitative predictive accuracy of a pathway-
based prediction model we obtained gene expression data from the
livers of mice dosed with 26 chemicals over a period of 90 days. All
the 26 chemicals were tested in a two-year bioassay in the same
strain of mice dosed via the same respective routes. Thus, the
differential liver carcinoma and adenoma rates between treated
and control animals from the results of the two-year bioassays are
known. Using the data, we derived pathway-based models to
predict the differential tumor rates at the end of a two-year
bioassay. The use of a pathway-based model would result in a
reduction of a model with around 6000 gene features to one with
around 200 pathways in the KEGG database [17,18,19]. The
model derived using the mouse data was then used to predict
carcinogenicity in appropriately chosen scenarios in rats and
humans.
Materials and Methods
Mice chemicals, animals and treatments
The chemical treatments used in the experiments on female
B6C3F1 mice are summarized in Table 1. Note the treatments are
the same as the maximum tolerable dose (MTD) used for the
corresponding chemical in the two-year bioassay. Treatments
involving lower doses of a subset of 5 chemicals from Table 1 are
provided in Table 2. More detailed descriptions of the chemicals,
treatments and gene expression analysis are provided in the
Text S1.
Rat liver gene expression data
To address the question of species extrapolation, gene
expression and tumor data from chemical exposures in Fischer
344 rats were obtained from the literature [5]. The chemical
treatments are summarized in Table S1. Additional information is
provided in the Text S1. Normalized probe intensity data for each
treatment were grouped separately with the control and normal-
ized using the quantile normalization function in MATLAB
(2008a, The MathWorks, Natick, MA).
Human gene data
The pathology review of the treated mice after 90 days of
exposure to hepatocarcinogens did not identify liver tumors (see
Text S1). Hence, the 90 day gene expression patterns are
potentially reflective of a pre-neoplastic state in the case of the
chemicals that are known hepatocarcinogens (as characterized by
the 2 year bioassay). We considered known risk factors for various
human diseases including liver cancer. Both genetic (i.e., single
nucleotide polymorphisms) and non-genetic (i.e., disease) risk
factors were considered.
Genetic risk factors in terms of single nucleotide polymorphisms
associated with various human diseases including liver cancer are
tabulated on databases like the Genetic Association Database [20].
Genes having polymorphisms associated with various human
cancers,Alzheimer’s disease and Schizophrenia were downloaded
from the database. Identifying non-genetic risk factors for liver
cancer has been an active research topic
[21,22,23,24,25,26,27,28]. Among the main factors contributing
to the risk are Hepatitis C and B virus [22,24,25], cirrhosis [21]
and diabetes [27,28]. The risks of liver cancer associated with
cirrhosis induced by Hepatitus C virus was estimated to be
comparable with cirrhosis induced by non-alcoholic steatohepatitis
(NASH) [29]. In fact NASH is correlated with characteristics of
metabolic syndrome like obesity and diabetes. Various human
gene expression datasets associated with these risk factors are
identified on the Gene Expression Omnibus (GEO) database [30].
The processed and normalized gene expression data were used as
is from the database except for cases where the data were
presented as intensity values. In these cases, the intensity values
were log2-transformed. The entire set of data sets associated with
risk factors for liver cancer is summarized in Table 3.
Biochemical pathways used in the analysis
The biochemical pathways used in the analysis in this paper
were obtained from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) Pathway database [17,18,19]. The data for the
set of genes involved in each of the pathways and their associated
interactions were downloaded via the KEGG API. All pathways in
the database were used. The list of 216 pathways that were
homologous across human, mice and rats species, along with their
mouse KEGG ids are reported in Table S2.
Structurally enhanced pathway enrichment analysis
(SEPEA)
SEPEA, a network based pathway enrichment method
described in detail in [31], was used to evaluate the linkage
between the gene expression data and the KEGG pathways.
Unlike traditional pathway enrichment methods that treat
pathways as sets of genes, SEPEA treats pathways as networks of
interacting proteins and/or enzymes. The genes corresponding to
Biological Networks for Predicting Carcinogenicity
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the proteins in the signaling network are given more weight
according to whether they are at the receptor or the terminating
end of the pathway that typically signals for transcription in a
number of genes. Further, pathways where the perturbed genes
are close relative to each other on the associated network are
modeled as being more likely to be affected than pathways where
the perturbed genes occur further apart over the network. There
were three analytic methods described in [31]; in the work
described here, SEPEA_NT2 is used [31] for the gene expression
analysis and SEPEA_NT3 for the gene polymorphism data. The
goal of the enrichment analysis is to assign significance (in terms of
p-values) to all chosen KEGG [17,18,19] human, rat and mouse
pathways for the increased likelihood of being affected in the livers
of the treated animals over the matched controls. The significance
obtained by SEPEA_NT2 were based on 56104 randomizations
(see [31] for details). For the analysis performed here, the SEPEA





where W refers to the standard normal distribution and Pij denotes
the p-value obtained using SEPEA for pathway j as a result of the
Table 1. Treatment groups and abbreviations used in the 90 day exposure to the 26 chemicals and corresponding vehicle controls
used in this study.
Chemical Short Name NTP No. Routea Dose Ames Assay Liver Tumorsb
1-Amino-2,4-dibromoanthraquinone ADBQ 383 F 20,000 ppm + Yes
Benzofuran BFUR 370 GC 240 mg/kg 2 Yes
Methylene Chloride MECL 306 I 4,000 ppm +,2,+ Yes
N-Methylolacrylamide MACR 352 GW 50 mg/kg 2 Yes
1,5-Naphthalenediamine NAPD 143 F 2,000 ppm + Yes
Tris(2,3-dibromopropyl)phosphate TDPP 76 F 1,000 ppm 2 Yes
2,2-Bis(bromomethyl)-1,3-propanediol BBMP 452 F 1,250 ppm +,+,2 No
1,2-Dibromoethane DBET 86 GC 62 mg/kg + No
Ethylene Oxide ETOX 326 I 100 ppm + No
Naphthalene NPTH 410 I 30 ppm 2 No
Vanadium Pentoxide VANP 507 I 2.0 mg/m3 2 No
Benzene BENZ 289 GC 100 mg/kg 2 Eqc
Coumarin COUM 422 GC 200 mg/kg + Eqc
1,2,3-Trichloropropane TCPN 384 GC 60 mg/kg +,+ Yes
1,4-Dichlorobenzene DCBZ 319 GC 600 mg/kg 2 Yes
Propylene glycol mono-t-butyl ether PGBE 515 I 1,200 ppm + Yes
Tetrafluoroethylene TFEL 450 I 1,250 ppm NA Yes
2-Chloromethylpyridine hydrochloride CMPH 178 GW 250 mg/kg + No
Diazinon DIAZ 137 F 200 ppm 2 No
Iodoform IODO 110 GC 93 mg/kg +,+ No
Malathion MALA 24 F 16,000 ppmd
(14,800 ppm)
2 No
N-(1-naphthyl) ethylenediamine dihydrochloride NEDD 168 F 3,000 ppm
(2,000 ppm)e
+ No
4-Nitroanthranilic acid NAAC 109 F 10,000 ppm +,+ No
Pentachloronitrobenzene PCNB 61 F 8,187 ppm 2 No
Tetrafluoroethane TFEA ---f I 50,000 ppm NA No
Trichlorofluoromethane TCFM 106 GC 3,925 mg/kg 2.2 No
Air ACON I
Corn oil CCON GC
Feed FCON F
Water WCON GW
aI = inhalation; F = feed; GC = gavage, corn oil (5 ml/kg); GW = gavage, deionized water (5 ml/kg).
bThe results for liver tumors were based on a p = 0.01 threshold for combined increase in adenomas or carcinomas.
cThe results for liver tumors in this study were considered equivocal or borderline significant. Combined increase in hepatocellular adenomas or carcinomas resulted in
p = 0.075 and p = 0.084 for benzene and coumarin respectively.
dDue to signs of toxicity, the 16,000 ppm dose was reduced to 0 ppm on day 9 for a period of 2 days. The dose was raised to 8,000 ppm for a period of 9 days and
returned to 16,000 ppm for the remainder of the study. The time weighted average dose was 14,800 ppm.
eThe initial dose of 3,000 ppm was reduced to 2,000 ppm in week 2 of the study due to taste aversion and weight loss. The 2,000 ppm dose is the same as the low dose
in the original bioassay.
fChemical not evaluated by the NTP. Bioassay performed by Alexander et al. [20].
doi:10.1371/journal.pone.0063308.t001
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mice being dosed with chemical i at a given dose or human data
set i.
Evaluation of carcinogenicity for mice chemical data
The carcinogenicity rate of a chemical is defined using the
survival-adjusted proportions of animals treated with the chemical
that developed liver adenomas or carcinomas and the corresponding
proportion for the control animals at the end of the two-year
bioassay. The data for all chemicals except tetrachloroethane [32]
were obtained from their respective technical reports for the two-
year cancer bioassay developed by the NTP(see Text S1 for
reference to the NTP technical reports). The poly-3 survival-
adjusted numbers [15,33] were used when available, else the survival
adjustment provided in the technical reports were used. The poly-3




























treat are the survival adjusted number and
proportion, respectively of animals treated with chemical i that
developed adenomas or carcinomas, ni
cont and pi
cont are the
corresponding terms for the control animals. To avoid outlier
effects in the analysis, zi = z2e25 was used when zi$z2e-5 where z2e25
is the critical value of the standard normal distribution correspond-
ing to 261025 significance.
Prediction model relating carcinogenicity to either
pathway features
The critical hypothesis of this manuscript is that the observed
changes in gene expression manifest at the pathway level have
adequate information to predict future carcinogenicity. However,
it is not obvious what mathematical functional form relates the
observed changes in pathways to the carcinogenicity predictions.
Specifically, the poly-3 statistic for a chemical obtained from the
two-year cancer bioassays is assumed to be functionally related to
the 90 day gene expression-based perturbation of the pathways
(obtained from the SEPEA analysis):
f (Zi1,Zi2, . . . ZiNp )~z i : i~1,2, . . . ,Nc ð3Þ
where Np represents the number of pathways (216, in the analysis
in this paper), Nc the number of chemicals (26 chemicals were
tested in mice). zi is given by Equation (2) and Zij is given by
Table 2. Dose response treatment groups and abbreviations used in the 90 day exposure with the results from the NTP rodent
cancer bioassay.
Chemical Short Name NTP No. Routea Dose
Dose Tested in
NTP Bioassay Liver Tumors
Methylene Chloride MECL5 306 I 4,000 ppm Yes Yes
MECL4 3,000 ppm No
MECL3 2,000 ppm Yes Yes
MECL2 500 ppm No
MECL1 100 ppm No
Naphthalene NPTH5 410 I 30 ppm Yes No
NPTH4 20 ppm No
NPTH3 10 ppm Yes No
NPTH2 3 ppm No
NPTH1 0.5 ppm No
1,2,3-Trichloropropane TCPN5 384 GC 60 mg/kg Yes Yes
TCPN4 40 mg/kg No
TCPN3 20 mg/kg Yes No
TCPN2 6 mg/kg Yes No
TCPN1 2 mg/kg No
Propylene glycol mono-t-butyl ether PGBE5 515 I 1200 ppm Yes Yes
PGBE4 800 ppm No
PGBE3 300 ppm Yes No
PGBE2 75 ppm Yes No
PGBE1 25 ppm No
1,4-Dichlorobenzene DCBZ5 319 GC 600 mg/kg Yes Yes
DCBZ4 500 mg/kg No
DCBZ3 400 mg/kg No
DCBZ2 300 mg/kg Yes No
DCBZ1 100 mg/kg No
The vehicle controls were the same as given in Table 1.
aI = inhalation; GC = gavage, corn oil (5 ml/kg).
doi:10.1371/journal.pone.0063308.t002
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Equation (1) for the pathway-specific predictor. Note, the model is
fit to data sets corresponding to chemical treatments in Table 1.
The framework of the so-called Super Learner [34] coded in the
SuperLearner package [35] in R [36] provides a reasonable way of
evaluating alternate functional forms in a cross-validation frame-
work. The functional forms tried include tree-based methods
(random forests [37], bagging, conditional tree forests), support
vector machines, loess polynomial regression, bayes generalized
linear models, sparse partial least squares regression and neural-
networks – the book [38] describes details of all of the these
algorithms except random forests. Unless otherwise specified the
default settings of these learning algorithms in the SuperLearner
package are used. The SuperLearner algorithm that is based on
the optimal continuous combination of the predictions of the other
algorithms and the Discrete SuperLearner that picks the best
predictor at each fold of cross-validation were used. The
performances of these algorithms were evaluated in terms of their
cross-validated risk [34].
Five-fold cross-validation was chosen where the chemicals in
each of the five folds were fixed (Table S3) and chosen so that
distribution of high and low carcinogenicity values in each fold was
more or less the same. Predictions for all the data sets were based
on this 5-fold cross validation framework. In order to get ‘honest’
predictions for the chemicals with data from mice, because these
chemical data are used to make predictions for the very same set of
chemicals, two levels of 5-folds cross-validation was implemented
using the CV.SuperLearner function implemented in the Super-
Learner package. Specifically, the predictions for the chemicals in
each of the 5 test sets (corresponding to the 5-folds) are derived
from an additional 5-fold cross-validation of the remaining 20 or
21 chemicals in the 5 training tests.
Evaluation of the results of the predictions
The two year cancer bioassay carcinogenicity calls of the
chemicals used in the mice and rats experiments along with the
continuous predictions from the model (Equation (3)) derived using
the mouse data are used to generate receiver-operator (ROC)
curves using the pROC package [39] in R [36]. The carcinoge-
nicity calls (carcinogenic or non-carcinogenic) are based on a
significance p-value threshold of 0.01 using the statistic given in
Equation (2)) Myristicin and isosafrole were untested chemicals
among the rat data and predictions for these were not used in
generating the ROC curves. For the case of the human data, all
gene expression data sets associated with risks for liver cancer were
considered positive for carcinogenicity. The data set of gene
polymorphisms associated with liver cancer was also considered
positive while all other gene polymorphism data sets were
considered negative. The ROC curve naturally defines notions
of false positives and false negatives at chosen levels of specificity
Table 3. Human data sets associated with risk for liver cancer that were used for carcinogenicity predictions.
IDa Risk factor Treatment comparison Experiment description
GDS2239 HCV 3 HCV core protein induced
vs 3 control
Hepatitis C virus core protein effect on hepatocyte cell line
GDS3347 Type 2
diabetes
10 normal and 10 diabetic Type 2 diabetes: cultured myotubes
GDS3656 Type I
diabetes




8 control and 7 alcoholic cirrhosis Post-alcoholism and post-hepatitis C cirrhosis
GSE10356_HC HCV
cirrhosis
8 control and 7 HCV cirrhosis Post-alcoholism and post-hepatitis C cirrhosis




5 control and 5 obese and
well-controlled DM
Expression data from liver of obese (with or without type 2
diabetes) and lean human subjects
GSE16415 Type 2
diabetes
5 normal and 5 diabetic Genome wide gene expression profiling of visceral adipose
tissue among Asian Indian diabetics
GSE20948_12 hrs HCV 3 Huh7 cells_JFH-1 Infected after 12 hours vs 3 Huh7
cells_Mock Infected after 12 hours
Effect of Hepatitis C Virus Infection on Host Gene Expression
GSE20948_18 hrs HCV 3 Huh7 cells_JFH-1 Infected after 18 hours vs 3 Huh7
cells_Mock Infected after 18 hours
Effect of Hepatitis C Virus Infection on Host Gene Expression
GSE20948_24 hrs HCV 3 Huh7 cells_JFH-1 Infected after 24 hours vs 3 Huh7
cells_Mock Infected after 24 hours
Effect of Hepatitis C Virus Infection on Host Gene Expression
GSE20948_48 hrs HCV 3 Huh7 cells_JFH-1 Infected after 48 hours vs 3 Huh7
cells_Mock Infected after 48 hours
Effect of Hepatitis C Virus Infection on Host Gene Expression
GSE23343 Type 2
diabetes
7 normal and 10 diabetic Expression data from human liver with or without type 2
diabetes
SNP set Genes with Single Nucleotide Polymorphisms (SNPs) associated with human bladder, brain, breast, cancer, cervical, colorectal, endometrial,
esophageal, gastric, head and neck, liver, lung, lymphoma, lymphoma-Hodgkins disease, ovarian, pancreatic, prostate, renal, skin-non melanoma,
testicular, thyroid, leukemia, leukemia-childhood acute lymphoblastic cancers and alzheimer’s and schizophrenia diseases
aThe first 13 data sets with IDs beginning GDS- or GSE- represent gene expression data obtained from GEO database (http://www.ncbi.nlm.nih.gov/geo/, accessed June
2009). The gene polymorphism data associated with various human diseases are obtained from the GAD database (http://geneticassociationdb.nih.gov/, accessed June
2009).
doi:10.1371/journal.pone.0063308.t003
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and sensitivity on the ROC curves. Additionally the area-under-
the-curve (AUC) measures [40] of the ROC curves.
Results, Discussion and Conclusions
Choice of prediction algorithm
Different prediction models were evaluated in terms of their 5-
fold cross-validated risk for fitting the model given by Equation (3)
(see Table S4). Random forest and support vector machines using
all the pathway features displayed the lowest cross-validated risk.
Random forests [37] (denoted by SL.randomForest.1_All in Ta-
ble S4) were because they provide a rigorous metric called
importance for each of the biochemical pathways used in the
prediction model. The importance of a pathway is a measure of how
much it contributes to increases the accuracy of the predictions.
Receiver-operator curves for the predictions in the three
species
The model derived using the mouse data was used to predict the
carcinogenicity in mice, rats and humans for the corresponding
data sets. In this manuscript, the predicted values were treated as
proxies for the continuous NTP carcinogenicity values in Equation
(2). The receiver-operator curves for the three species are shown in
Figure 1. The Area-Under-the-Curve (AUC) metric for both mice
and rats (0.66 and 0.74) are reasonably good while it was 0.91 for
humans. This is a very encouraging result suggesting the utility of
extrapolation of stated mice results to the case of humans. The fact
that the rat and human prediction performances were better than
that for the mice may seem surprising and counter-intuitive.
However, it should not be. For the data sets under consideration,
the performance of predictions from test sets (in this case those
from rats and humans) using the inferred prediction model
depends on how closely the majority of positive (negative) test sets
were to a majority of the elements of the positive (negative)
training set (in this case those from mice). The ‘closeness’ here is
measured in the pathway-response feature space. Therefore, the
mechanisms of hepatocarcinogenicity implied by the pathway
responses of the 26 chemicals in mice were enough to adequately
cover the corresponding mechanisms seen in the data sets from
rats and humans.
The false positives and false negatives in each of the three
species at a level of specificity between 56–75% (i.e., comparable
Type I error rate) is summarized are Table 4. A further discussion
of the identified false positives and false negatives is provided in
Text S1.
This paper presents results only for pathway-based prediction
models. Gene-based prediction models were also evaluated and
they showed a similar performance in terms of the AUC metric
(data not shown) [12]. Evaluated gene-based models for predicting
lung carcinogenicity using the same set of 26 chemicals as used in
this paper. The average AUC metric they observed using a range
of learning models was around 0.7.
Features of the prediction models
The importance measures for each of the pathway-based
features are reported in Table S2. The top fifteen pathways
ranked by their importance measures output from the random
forests learning algorithm are provided in Table 5. From the
KEGG pathway database [17,18,19], the broad categories in
which each of the pathways lie are also provided. Among these
broad categories, altered fatty acid metabolism is associated with
liver steatosis, leading to steatohepatitis and subsequently to an
inflamed liver, liver cell death including apoptosis, inflammation,
hepatocellular regeneration, stellate cell activation, and fibrogen-
esis, events that culminate in cirrhosis and liver cancer [41,42].
This could also explain the reason why the gene expression data
based on non-genetic risk factors like obesity, cirrhosis and
diabetes were predictive of chemical-induced hepatocarcinogene-
sis. Calcium signaling is associated proliferating cells [43] and also
along with cytochrome c in programmed cell death, apoptosis
[44,45]. Perturbed glycan synthesis has been found in ovarian
cancer [46] and human mammary, colon [47], hepatic [48,49],
and glial tumors [50]. Other pathways included those associated
with altered gene transcription and translation, xenobiotic,
vitamin and carbohydrate metabolism. A clustergram of the z-
transformed SEPEA p-values for all the pathways across the 26
chemicals used for the mouse data is shown in figure S1 (see Text
S1 for details of generation of the clustergram). The lack of
predictability especially for the case of mice (because prediction
was based on mice data) suggests plausible new features that are
not captured by the the pathway-based ones or that the set of 26
chemicals was not diverse enough in terms of having sufficient
number of chemicals with alternate mode-of-actions. Some
pathways such as Amyotrophic lateral sclerosis (ALS) may have
Figure 1. Receiver-operator characteristics (ROC) curves of
carcinogenicity predictions using the pathway-based predic-
tion models across three species. (a. Mice, b. Rats and c.
Humans) The legend in the sub-plots provides the area-under-the-
curve (AUC) for the corresponding ROC curve. The curves for mice, rats
and humans are based on datasets corresponding to those in Tables 1,
Table S1 and Table 3 respectively.
doi:10.1371/journal.pone.0063308.g001
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relatively large importance measures but may have no direct
significance to the biological processes in the liver. The
interpretation one should have in such cases is that the responses
of the set of genes associated with ALS disease process in the liver
are relevant to the prediction of hepatocarcinogenicity.
Dose-response predictions
The predicted dose response for the chemicals in Table 2 is
shown in Figure 2. The slopes of the curves and the p-values of the
alternate hypothesis that the slopes are positive are given in
Table 6. NPTH is the only non-liver carcinogen among the five
chemicals and had a negative slope. The responses derived from
the model produce larger positive and more significant (lower p-
values) slopes for the carcinogens. The fall in the carcinogenicity
responses across the two lowest doses for PGBE and TCPN could
be suggestive of alternate mode-of-actions at lower doses.
Conclusions
The analyses involved in this paper worked with hepatocarcin-
ogenicity prediction models trained using data from mice and
extrapolated to data sets from rats and humans. Alternate models
derived from rats to predict carcinogenicity in other species could
be attempted. This was not attempted here because of lack of
sufficient analogous two-year cancer assay data for the rat and
human data sets. The model derived here used data for chemicals
at their maximum tolerable dose (MTD) levels. It could be argued
that responses at lower doses are the ones with the most human
relevance. Again this was not attempted here because of lack of
sufficient number of chemicals dosed at lower levels. One
possibility of understanding chemical-specific low-dose mecha-
nisms would be the availability to a relatively large epidemiological
data set of exposed people (e.g., [51] demonstrates an example of
such a study for the case of workers exposed to benzene).
The mice used in the study lacked the genetic diversity of
humans. So, the extrapolations of carcinogenicity predictions to
human data has also to be viewed in the light of limitations in
addressing concerns of identifying and characterizing the risk to
susceptible populations. Populations could be considered suscep-
tible either based on their genetics, age, nutritional and physical
activity status and possibly other risk factors.
The B6C3F1 mice differ significantly from humans in the
etiology of hepatocellular carcinoma (HCC). The mice have a
relatively high background rate of developing HCC. In humans,
HCC is thought to arise in a background of chronic inflammation,
necrosis and regeneration, fibrosis and extracellular matrix
deposition [52]. In comparison, HCC in mice are not known to
arise under this background. Rather, a genetic event is assumed to
precede a stepwise progression to HCC in mice. There are also
known differences and similarities for the initiating genetic events
for HCC between mice and humans. Therefore there is certainly a
point in questioning the use of B6C3F1 mice when attempting to
understand the etiology of human HCC. The utility of using the
Table 4. False positives and false negatives predictions of predictors across the three species at appropriately chosen points on
the receiver-operator curves in Figure 1.
ROC curve False positives False negatives Sens Spec
Mice naac, iodo, nedd, coum, mala, pcnb, dbet abdq,macr,tdpp,tfel 0.6 0.56
Rats APAP, TYP, VtC ESG_LOW,SAF_LOW,MEG_LOW 0.7 0.67
Humans cancer of the cervix, endometrium, esophogus ,stomach, head
and neck, lung, , ovary, testicle and lymphoma, Hodgkins disease
GSE16415 0.93 0.58
doi:10.1371/journal.pone.0063308.t004
Table 5. Top 15 pathways of the fitted prediction model.
KEGG pathway Broad pathway category Importance Score
Drug metabolism Xenobiotics Biodegradation and Metabolism 1.62
Glyoxylate and dicarboxylate metabolism Carbohydrate metabolism 1.15
Pentose and glucuronate interconversions 1.13
Ascorbate and aldarate metabolism 1.13
O-Mannosyl glycan biosynthesis Glycan Biosynthesis and Metabolism 1.02
Apoptosis Cell Growth and Death 1.01
Calcium signaling pathway Signal Transduction 0.99
Retinol metabolism Metabolism of Cofactors and Vitamins 1.45
Thiamine metabolism 1.00
Ribosome Transcription and Translation 1.11
RNA polymerase 1.01
Arachidonic acid metabolism Lipid metabolism 1.93
Steroid hormone biosynthesis 1.09
Glycosphingolipid biosynthesis - globo series 1.04
Amyotrophic lateral sclerosis (ALS) Neurodegenerative Diseases 1.29
doi:10.1371/journal.pone.0063308.t005
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carcinogenicity results from existing rodent bioassays to the
context of humans have been questioned by Bruce Ames and
colleagues [53,54,55,56]. This concern was in light of the relatively
large proportion of tested chemicals being declared as rodent
carcinogens. Some of these chemicals occur naturally in human
dietary sources and others are being prescribed as pharmaceutical
drugs. The exposures to humans from these sources were at doses
much lower than what were used in the rodent bioassays. In fact
the high positive rates from the rodent bioassays were hypothe-
sized to have been caused by increased cell proliferation induced
by the relatively high doses of the tested chemicals. Specifically for
the data in this manuscript, none of the rodent liver carcinogens
are currently known to be associated with human liver cancer.
However, in the predictive toxicology context of the manuscript,
in spite of the known differences in etiologies, our hypothesis is that
gene expression levels of the precancerous lesions are the similar in
mice and humans. This hypothesis is validated by the relatively
high predictability of human hepatocarcinogenicity using an
independently derived predictive model using 90 day gene
expression data from B6C3F1 mice. Further, the work in
Hoeneroff et al suggests that this hypothesis is not without
justification. In their work the authors found similar gene
expression profiles in cells from HCCs obtained from mice and
human samples. The situation is analogous to the case of
azoxymethane induced colon cancer [57] in rodents being used
as a model of human colon cancer. So the mode of action (chronic
inflammation, increased proliferation or specific genetic events)
leading to the pre-cancerous lesions in humans and rodents may
be similar or different but once the precancerous state is reached
then one could hypothesize that (at least evolutionarily) both
species may follow similar paths to tumor formation and
progression.
In summary, we rigorously derive and evaluate a biochemical
pathway based hepatocarcinogenicity prediction model. Among
the set of alternate prediction models , random forests were found
to perform the best in terms of cross-validated risk. The model
used gene expression data from a given tissue at the end of a short
Figure 2. Dose-response predictions using the pathway-based prediction models for data of the chemicals tabulated in Table 2.
Dose response predictions for five chemicals (a. dcbz, b. mecl, c. npth, d. pgbe and e. tcpn) treated at four different doses in mice.
doi:10.1371/journal.pone.0063308.g002
Table 6. Slopes of the dose-response curves in Figure 2.
Chemical Slopea p-valueb
dcbz 0.137/100 mg/kg 0.09
mecl 0.158/500 ppm 0.12
npth 20.256/5 ppm 0.99
pgbe 0.207/200 ppm 0.09
tcpn 0.331/10 mg/kg 0.05
aThe slopes are in terms of changes in the predicted z values per change in
tabulated dose. b p-value for hypothesis testing the alternative that the
estimated slopes are positive.
doi:10.1371/journal.pone.0063308.t006
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term study to predict the risk for development of tumors at the end
of a longer period of time. Specifically, the model is evaluated
using gene expression data obtained from the liver of mice treated
with a range of 26 chemicals over a period of 90 days. The model
with the information on affected pathways derived using these
gene expression data had sufficient signal to adequately predict the
two-year liver carcinogenicity risk of the same chemicals as
evaluated in the National Toxicology Program’s two-year cancer
bioassay. The fact that the model was developed at the
biochemical pathway level allows one to reasonably expect
conserved behaviors of the chemicals at the pathway level across
multiple species. This belief was validated using the model
developed for mice to predict results in humans and rats. This
fact was observed in Figure 1.The use of pathways in the
carcinogenicity prediction model allowed a biologically based
reduction of the feature space of the classifier. The responses of the
various pathways suggested a complex interplay between them
leading to the carcinogenicity prediction. What was encouraging
was the excellent extrapolation for the case of human data.
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